Evaluation of Elabela Levels in Obese Individuals OBEZ BIREYLERDE ELABELA DÜZEYLERİNİN DEĞERLENDİRİLMESİ

Year 2024, Volume: 14 Issue: 2, 85 - 91, 14.06.2024

Neslihan Yeniel , Ayşen Caniklioğlu , Zeynep Tuğba Ozan , Müjgan Ercan , Muhammet Fevzi Polat

Abstract

Objective: Obesity is a condition that occurs as a result of excessive weight gain. Obesity is related with the
high risk of several diseases like cardiovascular diseases and diabetes mellitus. Elabela is a peptide that has
emerged recently and is known to affect food intake by binding to apelinergic receptors. This study aimed to
investigate the serum levels of Elabela in obese and non-obese individuals.
Material and Methods: This study involved 24 people with obesity and 25 healthy adult people as control
group. Height, weight, gender, age, waist-hip circumference, blood pressure of participants were recorded
and routine blood tests were measured. Serum concentrations of Elabela were determined using enzyme-
linked immunosorbent assay.
Results: When comparing the obese group to the controls, no statistically significant differences were observed
between the two groups in terms of diastolic blood pressure, blood urea nitrogen, creatinine, total
cholesterol, low density lipoprotein cholesterol and C-reactive protein. Similarly, both groups did not differ
statistically regarding Elabela levels. The obese group exhibited significantly elevated levels of body mass
index, waist/hip ratio, systolic blood pressure values, glucose, aspartate aminotransferase, alanine aminotransferase,
triglyceride, insulin, homeostatic model assessment for insulin resistance (HOMA-IR) compared
to the control group. The obese group demonstrated a significantly lower level of high-density lipoprotein
cholesterol in comparison to the control group.
Conclusion: In this study, it was found that there was no relationship between Elabela levels and obesity.
However, this issue needs to be supported by further studies to clarify.

Keywords

Evaluation of Elabela Levels in Obese Individuals, OBEZ BIREYLERDE ELABELA DÜZEYLERİNİN DEĞERLENDİRİLMESİ, Evaluation of Elabela Levels in Obese Individuals OBEZ BIREYLERDE ELABELA DÜZEYLERİNİN DEĞERLENDİRİLMESİ

References

• 1. Albuquerque D, Nóbrega C, Manco L, Padez C. The contribution of genetics and environment to obesity. Br Med Bull 2017;123:159–73.
• 2. World Obesity Day 2022 – Accelerating action to stop obesity. Available at: https://www.who.int/news/item/04-03-2022-world-obesity-day-2022-accelerating-action-to-stop-obesity. Accessed July 28, 2023.
• 3. Chng SC, Ho L, Tian J, Reversade B. ELABELA: a hormone essential for heart development signals via the apelin receptor. Dev Cell 2013;27:672–80.
• 4. Pauli A, Norris ML, Valen E, Chew GL, Gagnon JA, Zimmerman S, et al. Toddler: an embryonic signal that promotes cell movement via Apelin receptors. Science 2014;343:1248636.
• 5. Xu J, Chen L, Jiang Z, Li L. Biological functions of Elabela, a novel endogenous ligand of APJ receptor. J Cell Physiol 2018;233:6472–82.
• 6. Zhang Y, Wang Y, Lou Y, Luo M, Lu Y, Li Z, et al. Elabela, a newly discovered APJ ligand: Similarities and differences with Apelin. Peptides (NY) 2018;109:23–32.
• 7. Murza A, Sainsily X, Coquerel D, Côté J, Marx P, Besserer-Offroy É, et al. Discovery and Structure-Activity Relationship of a Bioactive Fragment of ELABELA that Modulates Vascular and Cardiac Functions. J Med Chem 2016;59:2962–72.
• 8. Wang Z, Yu D, Wang M, Wang Q, Kouznetsova J, Yang R, et al. Elabela-apelin receptor signaling pathway is functional in mammalian systems. Sci Rep 2015;5:8170.
• 9. Yang P, Read C, Kuc RE, Buonincontri G, Southwood M, Torella R, et al. Elabela/Toddler Is an Endogenous Agonist of the Apelin APJ Receptor in the Adult Cardiovascular System, and Exogenous Administration of the Peptide Compensates for the Downregulation of Its Expression in Pulmonary Arterial Hypertension. Circulation 2017;135:1160–73.
• 10. Schreiber C, Holditch S, Generous A, Ikeda Y. Sustained ELABELA Gene Therapy in High-salt Diet-induced Hypertensive Rats. Curr Gene Ther 2017;16:349–60.